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Abstract
Systematic collection of phenotypes and their correlation with molecular data has been proposed
as a useful method to advance in the study of disease. Although some databases for animal species
are being developed, progress in humans is slow, probably due to the multifactorial origin of many
human diseases and to the intricacy of accurately classifying phenotypes, among other factors. An
alternative approach has been to identify and to study individuals or families with very
characteristic, clinically relevant phenotypes. This strategy has shown increased efficiency to
identify the molecular features underlying such phenotypes. While on most occasions the subjects
selected for these studies presented harmful phenotypes, a few studies have been performed in
individuals with very favourable phenotypes. The consistent results achieved suggest that it seems
logical to further develop this strategy as a methodology to study human disease, including cancer.
The identification and the study with high-throughput techniques of individuals showing a
markedly decreased risk of developing cancer or of cancer patients presenting either an unusually
favourable prognosis or striking responses following a specific treatment, might be promising
ways to maximize the yield of this approach and to reveal the molecular causes that explain those
phenotypes and thus highlight useful therapeutic targets. This manuscript reviews the current
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status of selection of extreme phenotypes in cancer research and provides directions for future
development of this methodology.
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Introduction
Despite the fact that human beings share the vast majority of their genetic information, the
few remaining variations account for an astonishingly wide range of different phenotypes.
The importance of characterizing such differences is widely recognized by the scientific
community and enormous efforts are being made to understand their role in disease [1].
Indeed, a useful method to advance in this path has been to correlate molecular data with
phenotypes. The soundness of this strategy is straightforward and the development of
phenotype databases has already been proposed [2,3]. Yet, although such databases are
being generated for species such as yeasts [4] or rodents [5,6] and are under development for
human beings [7,8], progress is proceeding at a relatively slow pace due to the enormous
complexity of this task, which is at least in part caused by the multifactorial origin of many
diseases and by the intricacy of accurately classifying phenotypes.
In the meanwhile, a frequent approach has been to correlate molecular features in groups of
patients with their phenotypes, expressed as clinical variables, such as prognosis or
treatment effects. Some relevant examples of the use of this strategy in oncology are the
correlation between thymidylate synthase expression and efficacy of 5-fluorouracil in
digestive tumours [9]; or the identification of gene-expression profiles of prognostic value in
lymphoma [10] or breast cancer patients [11]. However, despite the significance of some
results, the conclusions reached by many studies are of uncertain clinical significance or
even contradictory [12]. This has led to the establishment of specific guidelines to validate
conclusions before their publication [12–14]. Several factors may cause these biases,
including methodological issues, such as retrospective data collection, limitations in
laboratory techniques or the biology of complex diseases [12,15], such as cancer, which
present multiplex phenotypes. In addition, classification of patients into subgroups with
good or bad evolution that present moderate differences, such as subtle improvements in
survival, from one to the other may lead to the identification of molecular features
associated with modest differences of borderline clinical relevance.
A useful and intuitive approach to circumvent some of these problems has been to select
individuals with very characteristic, clinically relevant phenotypes and to study the
underlying causes. This strategy assumes that these patients are the most informative and
thus should be studied separately, rather than being included in larger series of patients that
might dissipate the information that they can provide. Even though this strategy has allowed
the identification of relevant biological facts with great effectiveness, through the study of
reduced numbers of subjects, and has been proposed as a methodology for the study of
human disease [16–20], its use has not become widespread. This manuscript reviews the
current status of extreme phenotype selection in cancer research and provides relevant
examples that support its value, along with potential directions to further develop this
strategy.
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Selection of apparent phenotypes
Apparent phenotypes present characteristic attributes and therefore can be identified by
observation. Sometimes the phenotype is readily recognized, because its characteristics are
obvious. This is the case of the widely employed strategy of identifying gene mutations that
cause genetically inherited diseases [21]. Paradigmatic examples in oncology include
syndromes characterized by the development of multiple tumours, such as multiple
endocrine neoplasia, type 1 (MEN-1). The description of parathyroid, pancreatic and
pituitary tumours in autopsies of patients with acromegaly [22], and its familial association
[23,24] preceded by decades the identification of the MEN-1 tumour-suppressor oncogene
[25] and its mutations in affected individuals [26]. Another outstanding example is the
detection of mutations in BRCA-1, a gene that was identified in families that presented a
high incidence of early-onset breast carcinoma [27].
On other occasions the phenotypes are less evident and complex epidemiological studies are
required to identify them. An illustrative example is the Li-Fraumeni syndrome, described
through the identification of an increased incidence of rhabdomyosarcomas in siblings
following the review of over 20,000 children’s death certificates [28,29]. As in the previous
example, the identification of the phenotype allowed the hypothesis to be formulated that
eventually led to the detection of germ-line p53 mutations as the cause [30].
Finally, sometimes characteristic phenotypes are expressed only under certain
circumstances, such as after treatment administration. For example, the description of severe
toxicity after 5-fluorouracil administration [31] allowed the identification of the biochemical
[32] as well as the genetic underlying causes [33]. Another relevant example is the discovery
of the expression of epidermal growth factor receptor (EGFR) mutations in tumours of
patients responding to EGFR tyrosine-kinase inhibitors [34,35]. Paradoxically, in this setting
the study of a relatively low number of subjects yielded very relevant and clinically useful
results, in contrast to the modest conclusions obtained after studying thousands of patients
through conventional randomized trials [36–39], which assume that the benefit that the
treatment produces only in a group of patients is large enough to administer it to the whole
unselected population. Interestingly, the selection and study of patients with extreme
responses (most vs. least sensitive), extreme drug metabolisms (high vs. low) or extreme
toxic effects (no toxicity at high doses vs. high toxicity at low doses) following drug therapy
has been described by Nebert as a well defined methodology in clinical pharmacology, in a
manuscript that reviews studies in which this strategy has been successfully employed [16].
The same author and his collaborators have also described in detail the statistical rationale
that supports this methodology [40].
The common factor underlying all these examples is that the initial step was the
identification of the characteristic phenotypes. Subsequent study of the selected individuals
led to the identification of the molecular causes. The effectiveness of this strategy is notable,
because the number of subjects that need to be studied is relatively small. In addition, the
clinical relevance is high, because the attributes of the selected phenotypes are significant.
Therefore, we believe that this methodology should be further developed in cancer research.
Relevant case-selection should include cancer patients with very characteristic and
uncommon evolution. Currently, many advanced solid tumours are considered incurable and
result in short survival. Nonetheless, clinical experience shows that exceptions exist even
among the malignancies presenting the direst prognosis, and every oncologist treats patients
that are unexpectedly cured or that live far beyond their estimated prognosis. Even though
many of those cases are not published, some reports of long-term survivors of apparently
incurable tumours such as pancreatic cancer [41,42], gastric cancer [43–46], colon cancer
[47], small [48,49] and non-small-cell lung cancer [50,51] or multiple myeloma [52] can be
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found in the medical literature. Assuming that the diagnostic and staging work-up has been
correctly performed, these individuals may represent extreme phenotypes worthy of detailed
study. Similarly, patients presenting early-stage cancer that receive adequate treatment and
that either do not relapse despite presenting a high risk of recurrence or relapse despite a
very low risk of recurrence, might be interesting groups to study. A clinical example of the
former design would be to study patients with T1G3 bladder tumours that do not relapse and
patients that present low-grade papillary tumours that recur following adequate local
treatment. Patients showing extreme responses or toxic effects to a given treatment, as
suggested by Nebert [16], also constitute interesting phenotypes to identify and to study. In
fact, this methodological design deserves further consideration in the current scenario in
which hundreds of drugs are being developed, but only a few obtain regulatory approval,
based on conventional drug development methodology. Further development of multiple
drugs might be of clinical interest, even if they just show clinical activity in a limited
subgroup of patients, assuming that it would be possible to identify such patients. Studies in
which patients receive a treatment in a non-randomized fashion and those patients that
present marked benefit are intensively studied to elucidate specific markers of activity might
become complementary to current randomized studies. The sample size of these studies
should allow to identify a sufficient number of patients presenting clear benefit from the
treatment. Such studies might become a useful tool to further develop personalized
medicine, allowing identification of those patients that achieve a truly significant benefit
from a specific treatment.
Multiple potential causes might explain these phenotypes, and they could be related to host
and tumour factors as well as environmental causes (Fig. 1). Host factors might include
regulation of immune response, angiogenesis, apoptosis or DNA repair mechanisms, ability
to control metastasis or advantageous metabolism of anti-cancer treatments, among others.
Tumour factors might comprise abnormalities in drug or immune resistance, cell cycle and
apoptosis regulation, and so on. Since multiple hypotheses should be studied, the assessment
of specific major molecular pathways and the use of high-throughput techniques, which
allow the simultaneous assessment of multiple biological factors, seem necessary. Even
though the interpretations of these techniques is somewhat cumbersome, due to the large
amount of information they produce, the use of a reduced sample population that present
marked and clinically relevant characteristics should clearly improve the efficiency of such
studies.
This strategy has already been followed by some researchers. The study of melanoma
patients with long-term survival has highlighted tumour immune escape as a mechanism of
disease progression and shifting of T-cell responses as a response to this escape [53], as well
as prolonged persistence of specific CD8+ cells as a potential cause of maintenance of long
disease remissions [54,55]. Interestingly, all these observations, which support the concepts
of cancer immunosurveillance and immunoediting [56], were obtained from the study of just
4 patients. We have used this strategy in renal cell carcinoma patients treated with the
antiangiogenic drug sunitinib. Sera from 3 patients showing marked responses and from 3
patients that presented clear progressions were analyzed with a Human Cytokine Array,
which evaluates 174 cytokines. We identified 27 cytokines, which varied significantly
between both groups, and we further selected and assessed the most relevant cytokines by
ELISA in 21 evaluable patients, concluding that TNF-α and MMP-9 baseline levels were
predictive of response [57]. In a similar study performed in melanoma and renal cell-
carcinoma patients, vascular endothelial growth factor and fibronectin were identified as
predictors of response to high dose intravenous IL-2 [58]. Although these studies warrant
confirmation, they support the relevance of selection of patients with extreme phenotypes
and their study with high-throughput techniques as a valid method to identify candidate
predictive factors of drug activity.
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Selection of non-apparent phenotypes
Non-apparent phenotypes are those not associated with characteristic attributes and therefore
they cannot be identified by mere observation. An example is the existence of protection
against developing a disease. Since one specific disease does not develop in the majority of
individuals, the existence of protection cannot be distinguished from the simple absence of
disease by chance, unless the risk of developing that disease is taken into consideration.
It is well known that cancer incidence under similar environmental conditions is not
uniform. If cancer risk followed a normal distribution, as most biological variables do, we
could hypothesize that just as some individuals present an increased incidence, other
subjects may have lower incidence than expected. If these individuals exist, it would be
naïve to attribute their phenotype to chance, at least until other causes have been ruled out,
and their identification and study could increase our knowledge about cancer and yield
useful therapeutic targets. This protection could be secondary to many factors, including
specific mechanisms of DNA repair, cell cycle regulation, metabolism of carcinogens,
angiogenesis, apoptosis or immunological response among others (Fig. 1).
Although it seems reasonable that selection of individuals presenting decreased risk of
developing cancer might have been favoured by evolution to a certain extent, the question
remains if such subjects do really exist. Looking to other diseases, we can find relevant
examples, some of which have been successfully identified through selection of extreme
phenotypes. One outstanding paradigm is the identification of alterations in the gene
encoding the chemokine coreceptor CCR5 that confer complete protection against certain
strains of the human immunodeficiency virus (HIV) [59,60]. Since CCR5 mutations were
not associated with phenotypic abnormalities, they were only identified after observing that
some individuals highly exposed to HIV never developed the infection [61]. The study of
those individuals allowed the discovery of a relevant target in HIV investigation.
Returning to cancer, some preclinical studies support the biological plausibility of the
existence of protective mechanisms. A relevant example is the creation of a “super-p53”
mouse, carrying supernumerary p53 copies, which shows a decreased risk of developing
chemically induced tumours [62]. Although these mice and other similar models [63,64]
have been artificially developed, their relatively normal phenotypes raise the question of
whether similar phenomena could spontaneously occur and be selected for in nature. It is
known that small malignant tumours identified in autopsies or by high-performance imaging
tests outnumber the quantity of clinically overt cancers [65]. However, it is unknown
whether this is caused by protective mechanisms or if it is due to other reasons, such as
differences in tumour biology. The same questions arise when we analyse the different
sensitivity of individuals to carcinogens such as tobacco or the variations in clinical
aggressiveness of tumours in different patients: while large differences exist, it is difficult to
establish their causes.
Even if we assume that individuals bearing protection against developing cancer may exist,
the question of how to identify them remains. Several studies have assessed the protective
role of enzymatic polymorphisms with inconclusive results, as reviewed elsewhere [18].
Most compared cancer patients with normal individuals. Such a design offers the
disadvantage that, rather than true protection against cancer, normal subjects may just
present absence of disease with a normal risk of developing it. Instead, protection can be
expected in individuals not developing cancer despite presenting an increased risk. This
approach has been successfully evaluated in the study of polymorphisms of detoxifying
enzymes, using elderly individuals not presenting cancer as controls, sometimes even when
they were smokers [66–69]. While these studies truly select extreme phenotypes, their
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design could be improved by the use of high-throughput techniques, which study multiple
potential causes, rather than just a few; and by selecting individuals with even more
characteristic phenotypes, i.e., a markedly reduced individual or familial risk of developing
cancer. Families presenting very low cancer incidence across several generations might
show reduced familial risk. Subjects with high-risk cancer factors, such as extensive
exposure to carcinogens or cancer familial syndromes that do not develop the disease, or in
whom development is significantly delayed, may present reduced individual risk. Some
sensitive models that have already been proposed might be familial adenomatous polyposis
[18] or hereditary non-polyposis colorectal cancer [70], because they present high
penetrance and, therefore, the likelihood that an affected individual will not develop cancer
is low. The study of heavy smokers that do not develop cancer at an advanced age and of
young smokers who develop the disease might also yield relevant information on cancer
protective mechanisms and tumour development and growth. Different combinations of
these strategies could be developed. Aggregation of similar phenotypes within one family
would further support that their underlying cause is not random. Theoretically, the
likelihood of finding clinically relevant results should be directly related to the magnitude of
the discrepancy between the estimated risk of presenting cancer and the observed phenotype.
Conclusions and future directions
Extreme phenotype selection is a well defined biological concept that describes how
environmental pressures favour, among traits exhibiting diverse phenotypes, the fittest to
overcome the hazards encountered. Although it seems logical to study the favoured
phenotypes to determine their mechanisms of success, the use of this strategy has often been
restricted to obvious cases or to isolated observations made by discerning clinicians. The
lack of a systematic approach to the identification of extreme phenotypes is what has
probably precluded most of them from being studied. Therefore, a consistent methodology
should be developed to maximize the potential benefit of this strategy. Specifically in the
field of oncology, we propose the creation of databases compiling patient samples, together
with clinical and epidemiological data from individuals presenting relevant phenotypes. The
collection and intensive study of these extreme cases, rather than constituting a mere list of
oddities, might provide excellent hunting grounds to discover Achilles heels of cancer.
This methodology does, however, raise some issues. Principal among these are the questions
of how to classify phenotypes into quantitative groups [16] in order to define what
constitutes an extreme phenotype, and how to identify them. Definition of phenotypes that
might be clinically relevant and that can be found in clinical practice should probably be
performed by consensus panels of experienced clinicians under the coordination of medical
societies or cooperative groups. Case selection should be approached by training and
creating awareness among medical specialists. Cancer patients with very favourable
evolution, or with extreme responses or toxicities following therapy could be selected in
oncology centres relatively easily, since their number is small and their characteristics are
unusual. Individuals presenting cancer familial syndromes not developing cancer despite
their high risk could be selected through genetic counselling units. In other cases, more
complex epidemiological studies might be required to identify relevant discordances
between the expected and the observed phenotypes. Since it is unlikely that an adequate
number of subjects bearing extreme phenotypes can be detected in a limited number of
institutions, this will require the collaboration of large cooperative groups, ideally at an
international level.
Another issue is what variables should be studied in these subjects. Characteristic
phenotypes may be caused by host or tumour factors, as well as by external causes.
Therefore, all of these should be analyzed, and ideally samples from the tumour and from
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the host’s normal tissue should be collected, along with clinical and epidemiological data.
The type and quantity of the samples should allow a wide variety of studies to be performed,
including screening of cell genomes, epigenomic changes and transcriptomes through high-
throughput techniques, as mentioned above, such as Genome Wide Association Studies
(GWAS) or full genome sequencing. The samples should also permit additional studies to be
performed in the future using techniques that are not yet available. At a minimum, whole
blood, including serum and DNA and, in the case of cancer patients, fresh and paraffin-
embedded tumor tissue, should be collected. The obtention of sequential samples, linked to
relevant clinical events (e.g: start of a new treatment, evaluation of clinical response or
observation of an unexpected toxicity) might provide relevant information about the
evolution of different biomarkers in such situations. Even though this methodology does not
avoid the inherent problems of sample collection, it does limit dramatically the number of
samples to obtain and to study. Unavailability of samples might be an important limitation,
which could be overcome by prospective collection of cases. The importance of an adequate
infrastructure to collect and store samples and to manage the database cannot be
overemphasized. Lastly, ethical issues may be another point of concern, since the use of
biologic material is subject to strict regulations. Ethical boards must collaborate to make
these studies feasible without compromising the rights of the participants. The possibility of
contacting subjects in order to obtain more information or to perform functional studies
should be taken into consideration. Well designed informed consent processes and
prospective data collection should minimize these problems.
In conclusion, the selection and the study of extreme, clinically relevant phenotypes is an
efficient strategy to identify their underlying causes. The creation of collaborative databases
compiling biological samples and clinical information from such phenotypes might increase
our knowledge of cancer and provide new therapeutic strategies. This will require close and
continued collaboration between clinicians, who must identify appropriate cases, and basic
scientists, who should perform adequate studies to identify and integrate the relevant targets.
Even in the current age of modern molecular biology, clinical observation should remain a
preferred strategy to generate hypothesis than intellectual speculation.
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Fig. 1.
Flow chart representing the process from selection of extreme phenotypes to determination
of their molecular causes. Although the observation of extreme phenotypes clearly suggests
that there is indeed a needle in the haystack to find, it offers limited clues about the nature of
the causative mechanisms. Nonetheless, limiting the number of cases and tissue samples to
analyze provides a considerable degree of simplicity that to date has been largely neglected.
Initial screening of factors that might explain the phenotypes might be performed either by
studying specific major molecular pathways or applying high throughput techniques. Once
these potential clues have been identified, the specific underlying mechanisms should be
addressed in detail
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